文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

滤泡性淋巴瘤的表观基因组调控其微环境。

The follicular lymphoma epigenome regulates its microenvironment.

机构信息

Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE, USA.

Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

出版信息

J Exp Clin Cancer Res. 2022 Jan 12;41(1):21. doi: 10.1186/s13046-021-02234-9.


DOI:10.1186/s13046-021-02234-9
PMID:35022084
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8753841/
Abstract

Follicular lymphoma (FL) is a B-cell non-Hodgkin lymphoma of germinal center (GC) origin with a distinctive tumor microenvironment (TME) and a unique spectrum of mutations. Despite the important therapeutic advances, FL is still incurable. During B-cell development, the GC reaction is a complex multistep process in which epigenetic regulators dynamically induce or suppress transcriptional programs. In FL, epigenetic gene mutations perturb the regulation of these programs, changing GC B-cell function and skewing differentiation towards tumor cells and altering the microenvironment interactions. FL pathogenesis and malignant transformation are promoted by epigenetic reprogramming of GC B cells that alters the immunological synapse and niche. Despite the extensive characterization of FL epigenetic signature and TME, the functional consequences of epigenetic dysregulation on TME and niche plasticity need to be better characterized. In this review, first we describe the most frequent epigenomic alterations in FL (KMT2D, CREBBP and EZH2) that affect the immunological niche, and their potential consequences on the informational transfer between tumor B cells and their microenvironment. Then, we discuss the latest progress to harness epigenetic targets for inhibiting the FL microenvironment. Finally, we highlight unexplored research areas and outstanding questions that should be considered for a successful long-term treatment of FL.

摘要

滤泡性淋巴瘤(FL)是生发中心(GC)起源的 B 细胞非霍奇金淋巴瘤,具有独特的肿瘤微环境(TME)和独特的突变谱。尽管有重要的治疗进展,但 FL 仍然无法治愈。在 B 细胞发育过程中,GC 反应是一个复杂的多步骤过程,其中表观遗传调节剂动态诱导或抑制转录程序。在 FL 中,表观遗传基因突变会破坏这些程序的调节,改变 GC B 细胞的功能,并向肿瘤细胞分化倾斜,改变微环境相互作用。FL 的发病机制和恶性转化是由 GC B 细胞的表观遗传重编程促进的,这种重编程改变了免疫突触和龛位。尽管对 FL 的表观基因组学特征和 TME 进行了广泛的描述,但需要更好地描述表观遗传失调对 TME 和龛位可塑性的功能后果。在这篇综述中,我们首先描述了 FL 中最常见的表观遗传改变(KMT2D、CREBBP 和 EZH2),这些改变影响免疫龛位,及其对肿瘤 B 细胞与其微环境之间信息传递的潜在影响。然后,我们讨论了利用表观遗传靶点抑制 FL 微环境的最新进展。最后,我们强调了一些未被探索的研究领域和悬而未决的问题,这些问题应该在 FL 的成功长期治疗中得到考虑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1bd/8753841/7f347d2f83a9/13046_2021_2234_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1bd/8753841/7f347d2f83a9/13046_2021_2234_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1bd/8753841/7f347d2f83a9/13046_2021_2234_Fig1_HTML.jpg

相似文献

[1]
The follicular lymphoma epigenome regulates its microenvironment.

J Exp Clin Cancer Res. 2022-1-12

[2]
Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm.

Blood. 2024-3-21

[3]
Pathogenesis of follicular lymphoma.

Best Pract Res Clin Haematol. 2018-3

[4]
Chromatin modifying gene mutations in follicular lymphoma.

Blood. 2017-11-20

[5]
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.

Cancer Cell. 2020-5-11

[6]
Advances in the multi-omics landscape of follicular lymphoma.

Int J Biol Sci. 2023

[7]
New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.

Semin Oncol. 2018-10-23

[8]
Follicular lymphoma microenvironment: insights provided by single-cell analysis.

J Clin Exp Hematop. 2023-9-28

[9]
T follicular helper cells: a potential therapeutic target in follicular lymphoma.

Oncotarget. 2017-11-30

[10]
KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells.

Proc Natl Acad Sci U S A. 2023-3-14

引用本文的文献

[1]
Integration of gene mutations in risk prognostication for watch-and-wait follicular lymphoma patients initiating first-line treatment.

Hemasphere. 2025-5-7

[2]
Unraveling the complexity of follicular lymphoma: insights and innovations.

Am J Cancer Res. 2024-12-15

[3]
Bromodomain proteins as potential therapeutic targets for B-cell non-Hodgkin lymphoma.

Cell Biosci. 2024-11-23

[4]
Landscape of targeted therapies for lung squamous cell carcinoma.

Front Oncol. 2024-10-31

[5]
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience.

Haematologica. 2025-2-1

[6]
Applications of Multimodal Artificial Intelligence in Non-Hodgkin Lymphoma B Cells.

Biomedicines. 2024-8-5

[7]
Diffuse large B-cell lymphoma microenvironment displays a predominant macrophage infiltrate marked by a strong inflammatory signature.

Front Immunol. 2023

[8]
Microglia and metastases to the central nervous system: victim, ravager, or something else?

J Exp Clin Cancer Res. 2022-11-21

[9]
Editorial: B Cell Non-Hodgkin's Lymphoma & Tumor Microenvironment Crosstalk: An Epigenetic Matter?

Front Genet. 2022-5-19

[10]
Immune Epigenetic Crosstalk Between Malignant B Cells and the Tumor Microenvironment in B Cell Lymphoma.

Front Genet. 2022-2-14

本文引用的文献

[1]
Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations.

Cancers (Basel). 2021-4-25

[2]
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma.

Leukemia. 2021-9

[3]
Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma.

Blood. 2021-5-27

[4]
Harnessing lymphoma epigenetics to improve therapies.

Blood. 2020-11-19

[5]
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.

Lancet Oncol. 2020-10-6

[6]
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Lancet. 2020-9-1

[7]
Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.

Ann Pharmacother. 2021-3

[8]
Immunogenomic Landscape of Hematological Malignancies.

Cancer Cell. 2020-9-14

[9]
Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome.

J Exp Med. 2020-10-5

[10]
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.

Cancer Cell. 2020-5-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索